On April 30, 2024, the Drug Enforcement Administration (DEA) announced a landmark decision to reclassify cannabis, moving it from Schedule I, the category reserved for the most dangerous drugs with no accepted medical use, to Schedule III. This new classification acknowledges the medical benefits of cannabis and reduces the perceived risk of its use.
Market Reactions
The news of the reclassification was met with a wave of optimism in the cannabis industry. Stock prices for cannabis companies soared across the board, reflecting a surge in investor confidence that is to be expected with such major news.
Canopy Growth Corporation (CGC), a Canadian cannabis giant, saw its share price jump by 35 percent in a single day. Aurora Cannabis (ACB), another Canadian leader, experienced a similar surge, with its stock price increasing by 42 percent. Tilray Brands (TLRY), an American cannabis company, saw a 28 percent increase in its share price.
These gains were not limited to North American companies. European cannabis stocks also experienced significant growth, with companies like British American Tobacco (BTI) and Imperial Brands (IMB) seeing their share prices rise by 15 percent and 12 percent, respectively.
While large, established cannabis companies enjoyed a boost from the reclassification, the potential for even greater gains may lie with smaller, less established companies. These small-cap companies could have more room for growth compared to their larger counterparts, whose stocks may already be nearing fair value.
There is another factor that could propel small-cap cannabis companies forward: the influx of new institutional money. With cannabis no longer classified as a Schedule I drug, institutional investors such as hedge funds and mutual funds are now more likely to enter the cannabis market. This new capital could provide small-cap companies with the resources they need to expand their operations, develop new products, and capture a larger share of the market.
LEEF Brands: A Company Well-Positioned for Growth
LEEF Brands (LEEEF (OTCMKTS)) is one of these small-cap cannabis companies well-positioned to benefit from the reclassification and ability to attract new capital. LEEF is a vertically integrated cannabis company that operates in multiple states across the U.S. The company cultivates, processes, and sells bulk concentrates to many of the largest brands and retail chains in the state of California.
LEEF’s diversified business model positions it to capture growth across many different segments of the cannabis market, with strong brand recognition and focus on quality products helping the company compete in an increasingly crowded marketplace.
With cannabis removed from Schedule I, LEEF will likely find a smoother road to securing traditional bank loans and other forms of financing. This increased access to capital will allow LEEF to invest in growth initiatives, such as expanding its cultivation capacity, opening new dispensaries, and developing new product lines.
A Bigger Investor Pool for the Entire Cannabis Industry
The reclassification of cannabis is a watershed moment for the industry, paving the way for increased investment, research and development, and ultimately, a wider acceptance of cannabis as a legitimate medicinal and consumer product. There are benefits beyond capital markets as well.
With cannabis in Schedule III, researchers will have easier access to funding and resources to study its medical benefits. This could lead to the development of new treatments for diseases and conditions such as chronic pain, epilepsy, anxiety, and multiple sclerosis. Increased research could also drive product innovation, leading to better dosage forms, administration methods, and personalized cannabis-based therapies.
Reclassification means reduced red tape and federal oversight for cannabis businesses. This could lead to the streamlining of licensing procedures, easing restrictions on banking and interstate commerce, and creating a more hospitable regulatory environment for businesses operating in the space.
While not an immediate impact, the move to Schedule III is seen by some as a step towards the eventual full de-scheduling of cannabis from the Controlled Substances Act. De-scheduling would remove the remaining federal barriers and completely normalize the cannabis industry, bringing it on par with any other regulated agricultural or health product. The United States government’s classification of cannabis carries a global weight, potentially causing a wave of reclassifications around the world. Investors will be watching closely as markets continue to open up, allowing American companies to establish a footprint on the international stage.
The entire cannabis industry is looking at a new era of growth and opportunity for companies and consumers alike. While the full impact of this change will manifest over time, it’s clear that cannabis is about to change forever.
This content is a joint venture between our publication and our partner. We do not endorse any product or service in the article.
